Impacto de la pandemia de COVID-19 en la resistencia antimicrobiana de Klebsiella pneumoniae y Acinetobacter baumannii en una unidad de cuidados intensivos
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2026.235692Palabras clave:
COVID-19, Bacterial resistance, Healthcare-associated infectionResumen
Introducción: La pandemia de COVID-19 tuvo impactos significativos en la prevalencia de infecciones hospitalarias y en la resistencia antimicrobiana de patógenos críticos, como Klebsiella pneumoniae y Acinetobacter baumannii. Objetivos: Analizar los cambios en la sensibilidad de estos microorganismos y sus consecuencias para el control de infecciones hospitalarias. Métodos: Estudio de cohorte retrospectivo, dividido en período Pre-pandémico (1 de septiembre de 2018 al 28 de febrero de 2020) y período Pandémico (1 de marzo de 2020 al 31 de agosto de 2021), incluyendo pacientes adultos ingresados en la Unidad de Cuidados Intensivos. Se analizó la incidencia de Klebsiella pneumoniae y Acinetobacter baumannii, y sus respectivos perfiles de resistencia antimicrobiana, además de la densidad de incidencia de las Infecciones Asociadas a la Atención Sanitaria (IAAS), comparando ambos períodos. Resultados: Entre las infecciones, se observó un aumento en la densidad de incidencia únicamente de la Neumonía Asociada a la Ventilación Mecánica (NAVM). En cuanto a las bacterias de interés, hubo un aumento en la prevalencia de Klebsiella pneumoniae (de 8.2% a 21.9% de cultivos positivos/total de pacientes) y de Acinetobacter baumannii (de 7.5% a 21.7% de cultivos positivos/total de pacientes), junto con un cambio en el perfil de sensibilidad. Conclusión: A partir de los resultados, se puede inferir que hubo un impacto significativo de la pandemia de COVID-19 en la prevalencia y en el perfil de resistencia antimicrobiana de ambas bacterias estudiadas, junto con un aumento en los reportes de Neumonía Asociada a la Ventilación Mecánica.
Descargas
Referencias
1-SAMPAIO, J. L. M.; GALES, A. C. Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins. Brazilian Journal of Microbiology, v. 47, p. 31-37, 1 dez.2016.
2-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Member States information session on infection prevention and control (IPC). Overview of the IPC situation Worldwide: highlights of achievement and gaps. Março 2022.
3-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global report on infection and prevention control. OMS, 2022.
4- VINCENT, J.-L. Nosocomial infections in adult intensive-care units. The Lancet, v. 361, n. 9374, p. 2068-2077, jun. 2003.
5- KOLLEF, M.H. et al. Nosocomial infection. Critical care medicine, v. 49, n. 2, pg. 169-187, 14 jan. 2021.
6- VINCENT, J.-L., et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA, v. 302, n. 21, p. 2323, 2 dez. 2009.
7- VINCENT, J.-L., et al. Prevalence and outcomes of infections among patients in intensive care units in 2017. JAMA, v. 323, n. 15, p. 1478 - 1487, 21 abr. 2020.
8- SILVA, E. et al. Prevalência e desfechos clínicos de infecções em UTIs brasileiras: subanálise do estudo EPIC II. Revista Brasileira de Terapia Intensiva, v. 24, n. 2, p. 143-150, jun. 2012.
9- BRAGA, I. A. et al. Multi-hospital point prevalence study of healthcare-associated infections in 28 adult intensive care units in Brazil. Journal of Hospital Infection, v. 99, n. 3, p. 318–324, jul. 2018.
10- MAGILL, S. S. et al. Changes in Prevalence of Health Care- Associated Infections in U.S Hospitals. New England Journal of Medicine, v. 379, n. 18, p. 1732-1744, nov. 2018.
11-DESPOTOVIC, A. et al. Hospital acquired infections in the adult intensive care unit- Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. American Journal of Infection Control, v. 48, n. 10, p. 1211-1215, out. 2020.
12- Agência Nacional de Vigilância Sanitária. Programa Nacional de Prevenção e Controle de Infecções Relacionadas à Assistência à Saúde (PNPCIRAS) 2021 a 2025. ANVISA. Brasília, 05 mar. 2021.
13- Agência Nacional de Vigilância Sanitária. Critérios diagnósticos de infecções relacionadas à assistência à saúde. 1st ed. Brasília, Brasil: ANVISA; 2013.
14- SCHABERG, D. R.; CULVER, D.H.; GAYNES, R.P. Major trends in the microbial etiology of nosocomial infection. The American Journal of Medicine, v. 91, n. 3, p. S72-S75, set. 1991.
15- WEINSTEIN, R. A.; GAYNES R.; EDWARDS, J. R. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clinical Infectious Diseases, v. 41, n. 6, p. 848-854, 15 set. 2005.
16- VINCENT, J. L. The Prevalence of Nosocomial Infection in Intensive Care Units in Europe.JAMA, v.274, n. 8, p. 634-644, 23 ago. 1995 Agosto, 1995.
17- MAGIORAKOS, A-P. et al. Multidrug-resistant, extensively drug resistant and pandrug-resistant bacteria: an international expert proposal of interim standard definitions of acquired resistance. Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, v. 18, n. 3, p. 268-81, 2012.
18- ANG, H.; SUN, X. Risk factors for multidrug-resistant gram-negative bacteria infection in intensive care units: A meta-analysis. International Journal of Nursing Practice, v. 24, n. 4, p. e12644, 25 mar. 2018.
19- ANDRADE, L.N.; COSTA DARINI, A.L. Beta-lactamase-producing gram-negative bacilli: which bla bla bla is this?. Journal of Infection Control, v. 6, n.1, p. 16-25, jan, 2017.
20- SADER,H. S. et al. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagnostic Microbiology and Infectious Disease, v. 28, n. 2, p. 87-92, jun. 1997.
21- BUSH, K.; JACOBY, G. A. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy, v. 54, n. 3, p. 969-976, 7 dez. 2009.
22- HARRIS, P. N. A.; TMBYAH, P. A.; PATERSON, D. L. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? The Lancet Infectious Diseases, v. 15, n. 4, p. 475–485, abr. 2015.
23- JONES, R. N.; MARSHALL, S. A. Antimicrobial activity of cefepime tested against bush group I β-lactamase-producing strains resistant to ceftazidime a multilaboratory national and international clinical isolate study. Diagnostic Microbiology and Infectious Disease, v. 19, n. 1, p. 33-38, maio 1994.
24- MONTEIRO, J. et al. First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil. Antimicrobial Agents and Chemotherapy, v. 53, n. 1, p. 333–334, jan. 2009.
25- NORDMANN, P.; POIREL, L. Emerging carbapenemases in Gram-negative aerobes. Clinical Microbiology and Infection, v. 8, n. 6, p. 321-331, jun. 2002.
26-SOUZA GUSATTI C. et al. First occurrence of bla OXA-58 in Acinetobacter baumannii isolated from clinical sample in Southern Brazil. Brazil Journal and Microbiology. v.43, n.1, p.243-246. Jan.2012.
27- GALES, A. C. et al. Emerging Importance of Multidrug-Resistant Acinetobacter Species and Stenotrophomonas maltophilas Pathogens in Seriously Ill Patients: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clinical Infectious Diseases, v. 32, n. s2, p. S104-S113, 15 maio 2001
28- PAGANO, M. et al. Comparative Analysis of Carbapenem-Resistant Acinetobacter baumannii Sequence Types in Southern Brazil: From the First Outbreak (2007-2008) to the Endemic Period (2013-2014). Microbial Drug Resistance, v.25, n.4, p.538-542, maio 2019
29- MARTINS, A. F. et al. High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. American Journal of Infection Control, v. 40, n.2, p. 108-112, mar. 2012
30- DOI, Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, v.69, n.Supplement_7, p. S565-S575, 13 nov. 2019.
31- BORTOLLETI, F. et al. Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil. Emerging Infectious Diseases, v.22, n.10, p. 1849-1851, out. 2016.
32- LIMA, W. G. et al. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analyisis. European Journal of Clinical Microbiology & Infectious Diseases, v. 39, n. 8, p. 1427-1438, 12 jun.2020.
33- GENTELUCI, G. L. et al. Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2016.
34- PEREZ, L. R. R. et al. A four-year follow-up survey of antimicrobial resistance among Acinetobacter baumannii complex from inpatients in Southern Brazil. American Journal of Infection Control, v. 49, n.12, p.150-1505, dez.2021
35- ZHU, N. et al. A Novel Coronavirus from Patients with Pneumoniae in China, 2019. New England Journal of Medicine, v.382, n.8, 24 jan. 2020.
36- GUAN, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, v. 382, n. 18, 28 fev.2020.
37- RUUSKANEN, O. et al. Viral pneumonia. Lancet (London, England), v. 377, n. 9773, p. 1264-75, 2011.
38- RAWSON, T. M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clinical Infectious Diseases, v. 71, n. 9, 2 maio 2020.
39- LANGFORD, B. J. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection, jan. 2021.
40- GOYAL, P. et al. Clinical Characteristics of Covid-19 IN New York City. New England Journal of Medicine, 17 abr. 2020.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Gilberto Gambero Gaspar, Yasmim Saab Messias, Rodrigo de Carvalho Santana

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.



